Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of pharmacy-benefit manager Express Scripts
So what: The shares have taken a beating on cost concerns associated with its proposed $29 billion buyout of rival MedcoHealth Solutions
Now what: Express Scripts remains a pretty attractive long-term opportunity. "In spite of near-term headwinds and a challenging macroeconomic environment," said Chairman and CEO George Paz, "we remain confident we are well-positioned for continued growth." In fact, the company's fiscal forecasts through 2014 -- disclosed in a securities filing on the merger -- were also much higher than analysts had expected, offering investors even more comfort regarding the Medco buy.
Interested in more info on Express Scripts? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Medco. Try any of our Foolish newsletter services free for 30 days.